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annual questionnaire that was specifically designed to assess the symptoms and 
problems of the disease. Results: We review our results of over 10 years of follow-
up, and discuss the survey’s contribution to the field. Tracking 408 Pompe patients 
between 2002 and 2013, the cumulative data reveals the broad range of clinical man-
ifestations that interfere with patients’ lives. The survey allowed us to quantify the 
rate of disease progression and the positive effects of ERT on patients’ quality of life, 
fatigue, and participation in daily life. Furthermore, it showed for the first time that 
survival is reduced in adult Pompe disease and improved by ERT. ConClusions: 
Our results show that a patient survey can serve as a valuable and reliable tool for 
obtaining quantifiable information on the natural course of a rare disease and on 
the effects of therapy in a large cohort over a very long time. Most importantly, by 
working with patient reported outcomes, the survey provides the data that is truly 
relevant to the patient and complementary to clinical datasets.
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objeCtives: To conduct a systematic review of the literature and assess the impact 
of orthopaedic surgery on the health-related quality of life (HRQoL) of haemophilia 
patients with or without inhibitors. Methods: Searches were conducted in the 
MEDLINE, EMBASE, EconLit, Cochrane library and the Center for Reviews and 
Dissemination databases from 2000 onwards. A broad search including both Medical 
Subject Heading (MeSH) terms and key words related to haemophilia and HRQoL 
was conducted. We included only the publications reporting pre- and post-surgery 
HRQoL data and all orthopedic interventions were considered. Congress abstracts 
from 2010 were also reviewed. Abstracts and full text articles were screened by 
two reviewers and conflicts arbitrated. Results: A total of 1,471 articles were 
retrieved. Following the screening process, 8 full-text articles reporting pre- and 
post-surgery HRQoL data for patients who received ankle arthrodesis, total knee 
replacement, ankle replacement or hip arthroplasty were included. Seven studies 
used patient-reported measures and only one study estimated the EQ-5D using 
indirect matching techniques. Of the seven studies, four used the visual analogue 
scale (VAS). Three concluded that post-operative pain was significantly lower and 
only one study reported that although pain decreased post-surgery, moderate pain 
remained among patients who underwent multiple joint procedures and received 
ankle arthrodesis. Of the four studies that reported SF-36/SF-12 scores, significant 
gains in physical health scores were observed in three and higher mental health 
scores were reported in one study. Disease-specific measures, Western Ontario and 
McMaster University (WOMAC) and Oxford Knee Score, were assessed by two studies 
and improvements in pain and physical functioning were observed on both scales. 
Evidence from SF-12 summary scores suggests that the improvements in physical 
functioning are similar for patients with and without inhibitors. ConClusions: 
Orthopaedic surgery improves the HRQoL of haemophilia patients with severe 
arthropathy.
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objeCtives: When applying accepted health economic methods, it is not uncom-
mon to find valuations of patients’ health states that are worse than dead. 
Hypothetical valuations (the UK value set) of states according to the EQ-5D resulted 
in 82 of 243 possible states being valued as worse than dead. The presence of health 
states valued worse than dead risks giving rise to counter-intuitive consequences 
when incorporated in health economic analyses. The purpose of this study was 
therefor to investigate the presence of such states in an exposed population, namely 
people 65 years and older. Methods: Based on a Swedish epidemiological popu-
lation survey study directed to 10 000 persons 65 years and older the occurrence 
of states worse than dead were investigated and related to prevalence and inten-
sity of chronic pain. Results: Health states worse than dead were found in 1.8 % 
of the 6618 responders to the questionnaire. Among persons with severe chronic 
pain the prevalence was 16.7 % and among persons with moderate and no or mild 
chronic pain the prevalence of states worse than dead were 2.7 % and 0.8 % respec-
tively. Prevalence of these states clearly increased with age and female gender. Of 
women 85 years and older with severe chronic pain 38.7 % were in states worse 
than dead. ConClusions: Health states worse than dead are not rare in an elderly 
population and covariate with chronic pain, age and female gender. The prevalence 
of states worse than dead are highly dependent on the value set applied, and will 
have consequences for assessments of treatments for elderly with chronic pain. 
Based on the results of this study it should be investigated whether and to what 
extent health states worse than dead exist when using experience based valuation 
methods, which is the preferred approach in some settings/countries.
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and SSC. Average utilities for each health state were predicted from the regression 
coefficients. Utilities were also estimated using individual health state dummy 
variables in a sensitivity analysis. Results: Utilities for health states without BP 
or SSC were 0.76 for mild, 0.69 for moderate, 0.64 for marked, and 0.60 for severe. 
The utilities for states with bone symptoms were lower: 0.67 for mild+BP, 0. 68 
for mild+SSC, 0.61 for moderate+SSC, 0.56 for marked+SSC, and 0.52 severe+SSC. 
Sensitivity analysis utilities were similar but less precise and sometimes less clini-
cally plausible. ConClusions: Compared with the norm for the EQ-5D utility index 
in the UK (0.86), these utility estimates reflect the substantial quality of life impact 
of GD1, especially with skeletal complications. These utilities can be used in future 
economic evaluations of GD1 therapies to calculate quality-adjusted life years.
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objeCtives: In the past few years, a number of biological drugs to treat pemphigus 
have successfully passed through phase 2 and 3; however, none of the clinical trials 
in pemphigus has used preference-based outcome measures to generate utilities 
for economic evaluations, so far. In attempt to fill this gap, the objective of this 
study is to measure utility weights for hypothetical pemphigus vulgaris (PV) and 
foliaceus (PF) health states in a general population sample. Methods: Three health 
state profiles were developed: an uncontrolled PV, an uncontrolled PF and a treated 
pemphigus state. Health state vignettes combined a description of living with pem-
phigus including skin and mucosal symptoms, possible food avoidance, bathing/
clothing issues, and effects on work and social life. Utilities were obtained from 
a convenience sample of 106 adults using visual analogue scale (VAS, 0-10 scale) 
and time trade-off (TTO). Lead-time TTO was applied for health states considered 
worse than dead. Utilities in this study were ranging between -1 (lower anchor of 
worse than dead) and 1 (perfect health) Results: Mean VAS scores for PV, PF and 
treated pemphigus were 2.46±1.54, 3.77±1.69 and 6.35±1.60, respectively. The esti-
mated utility weights attached for the health states were as follows: PV 0.34±0.38, 
PF 0.51±0.31 and treated pemphigus 0.73±0.31. Overall 13% and 5% judged PV and 
PF as being worse than dead. For both VAS and TTO values, significant difference 
revealed between each of the three health states (p< 0.001). ConClusions: This 
study provides the first utility weights in pemphigus. Disutility associated with 
uncontrolled pemphigus was found worse than in uncontrolled psoriasis or atopic 
dermatitis. Successful treatment of pemphigus may yield significant utility gain 
(0.22-0.39). Utilities elicited in this study may be used in cost-effectiveness analysis 
of new pemphigus treatments.
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objeCtives: Treatment options for patients with hepatitis C have made tremen-
dous progress in the last 5 years. Innovative antiviral-therapies promise a huge 
reduction of burden of disease and side-effects accompanied by an increase of 
patient’s benefit. It is unclear, however, what properties generate the highest benefit 
for patients. Methods: A systematic literature search was conducted to identify 
patient-relevant outcomes . Within N= 14 semi-structured interviews the decision 
model was generated. Eight patient relevant characteristics were identified and 
described by three or six levels. For the discrete choice experiment, an experimen-
tal design (3*3+5*6) was generated using Ngene-Software. The design consisted 72 
choices, which were divided into 6 blocks. The survey was conducted in august 2014 
with computer-assisted personal interviews. Results: N= 561 hepatitis C-patients 
(58,1% male) within different treatment states participated. The preference analysis 
(random parameter logit estimation (with 95%CI)) showed a predominance for the 
attribute “sustained virological response 6 month after end of treatment”(coef.:1,108). 
A split second rank is occupied by the possible side effects “anemia”(coef.:0.396) and 
“rash”(coef.:0.372). The attributes that describe the administration of the treatment 
“number of interferon injections” (coef.:0.224) and “duration of treatment”(coef.:0.183) 
share the third place. The attributes “fatigue/exhaustion”(coef.:0.088) and “nausea/
diarrhea”(coef.:0.067) follow. Within the treatment decision of hepatitis C-patients 
the attribute “headache”(coef.:0.036) was not taken into account, as reflected by the 
lack of significance. ConClusions: In this study, the essential decision criteria 
for an optimal antiviral therapy of hepatitis C from the Hep C patients’ view were 
obtained by using a DCE. Thereby SVR is ranked highest against all patient relevant 
side effects and mode of administration characteristics. In the context of this study 
it could be demonstrated that with the help of the DCE patient-relevant properties 
can be weighted in terms of possible treatment options. The DCE stands out by a high 
degree of realism and good handling for the patient.
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objeCtives: Pompe disease is a rare, progressive lysosomal storage disorder for 
which enzyme therapy (ERT) became available in 2006. Four years earlier, the IPA/
Erasmus MC survey, an international longitudinal prospective survey, was estab-
lished to collect information on the natural course of the disease and its burden on 
patients. Methods: The survey is a collaboration between Erasmus MC University 
Medical Center and the International Pompe Association (IPA) and comprises an 
